David G. Huntsman

The University of British Columbia
Country flagCanada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (43)

Kaplan–Meier curves of OS in ( A ) main tumor groups ( n = 582)—MBOT, MOC, LGI, and UGI; ( B ) patients with MOC by FIGO stage ( n = 184); ( C ) patients with MOC by pattern of invasion in all stages ( n = 178); and ( D ) patients with stage I MOC ( n = 134), by pattern of invasion.

Year:

2025

Schema of study numbers for each analysis to describe different cohort numbers due to pathology review and missing data. MOC, mucinous ovarian carcinoma; MBOT, mucinous borderline ovarian tumor; LGI, lower gastrointestinal; UGI, upper gastrointestinal; SISH, silver in situ hybridization.

Year:

2025

Heat map of unsupervised clustering analysis. Contains all samples with a concordant pathology diagnosis ( n = 497), with MOC grouped by FIGO stage. Labels show main clusters and diagnoses. Gene-expression values are normalized and logarithm base 2 transformed. dx, diagnosis.

Year:

2025

Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare, aggressive cancer affecting young women driven by inactivating mutations in SMARCA4 , a key SWI/SNF chromatin remodeling gene. To uncover its druggable vulnerabilities, we performed a compound screen and found that SCCOHT cells and tumors were sensitive to PARP inhibitors. Paradoxically, SCCOHT displayed BRCA-deficient traits despite retaining wild-type BRCA1 expression. Elevated R-loop in SCCOHT sequestered BRCA1, limiting its availability for DNA damage repair. Proximity-dependent biotin identification revealed that wild-type SMARCA4, but not its pathogenic variants, promoted RNA polymerase II (Pol II) elongation by mediating the assembly of the polymerase-associated factor 1 complex. Thus, SMARCA4 loss increased Pol II pausing, resulting in elevated R-loops and BRCA1 redistribution. The suppression of BRCA1 activity sensitized SMARCA4-deficient SCCOHT cells and tumors to PARP inhibitors, which was further enhanced by the addition of a CDK9 inhibitor targeting Pol II elongation. Cotargeting PARP/CDK9 also elicited synergistic effects against other undifferentiated ovarian cancer cells with SMARCA4 loss. These findings link SMARCA4 loss to perturbed Pol II elongation and compromised DNA repair by BRCA1, providing a therapeutic opportunity to target SCCOHT and other SWI/SNF-deficient ovarian cancers. Significance: Pol II stalling induced by SMARCA4 loss leads to R-loop accumulation that sequesters BRCA1 to transcription complexes, underlying the sensitivity of SMARCA4-deficient ovarian cancers to inhibitors targeting PARPs and Pol II elongation.

Year:

2025

Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is a rare, deadly form of ovarian cancer that uniformly harbors mutations in SMARCA4, a member of the SWI/SNF chromatin remodeling complex. SWI/SNF impacts RNA splicing, and dysregulation of splicing can generate immunogenic tumor antigens. In this study, we explored the relationship between SMARCA4 loss and RNA splicing dysregulation. SCCOHT primary tumors harbored tumor-associated outlier splicing events compared with normal tissues. Many of the tumor events were retained introns encoding novel peptides predicted to bind to MHC-I complexes. Immune cells were observed in primary SCCOHT tumors, suggesting a potentially immune-reactive tumor microenvironment. Mutations in several switch/sucrose nonfermenting (SWI/SNF) subunits were associated with higher rates of outlier retained introns across tumor types in The Cancer Genome Atlas data. Interestingly, RNA sequencing of isogenic SCCOHT cell lines demonstrated a role for SMARCA4 in intron retention (IR). Distinct protein–protein interactions between splicing factors identified in SCCOHT cell lines supported a role for SMARCA4 in splicing regulation. Furthermore, SWI/SNF localized to genes, which were differentially spliced. Mass spectrometry analyses confirmed expression of some of these novel peptides, and a subset of these are predicted to bind to MHC-I complexes. A pool of these novel peptides derived from retained introns in SCCOHT triggered proliferation and expression of TNFα and INFγ in primary human T cells. Together, these data suggest that SMARCA4 loss in SCCOHT leads to IR. Furthermore, T-cell activation by novel peptides encoded by these tumor-specific splicing events suggests IR could be a source of tumor-associated antigens in SCCOHT. Significance: SCCOHT, a rare ovarian cancer, features splicing dysregulation due to SMARCA4 loss that generates immunostimulatory peptides linked to potential immune responses and therapeutic avenues, challenging traditional views of the role of SMARCA4.

Year:

2025

Clear cell ovarian cancer (CCOC) is the second most common ovarian cancer subtype, accounting for 5%–11% of ovarian cancers in North America. Late‐stage CCOC is associated with a worse prognosis compared to other ovarian cancer histotypes, a challenge that has seen limited progress in recent decades. CCOC typically originates within the toxic microenvironment of endometriotic ovarian cysts and is characterized by its intrinsic chemoresistance, a strong hypoxic signature, and abundant expression of cystathionine gamma‐lyase (CTH). CTH is a key enzyme in the transsulfuration pathway and serves as a marker of ciliated cells derived from the Müllerian tract. CTH plays a pivotal role in de novo cysteine synthesis, which is essential for glutathione (GSH) production and redox homeostasis. Using an array of molecular tools and cancer models, including in vivo studies, we demonstrated that CTH expression was induced under various stress conditions, such as exposure to endometriotic cyst content and hypoxia. This induction enables cell survival and creates a differentiation state manifested by CCOC that potentiates tumor progression and metastasis. In addition to regulating redox homeostasis, CTH enhances hypoxia inducible factor 1‐alpha (HIF1α) expression, independently of hydrogen sulfide (H 2 S) production. Re‐expression of HIF1α in CTH KO cells fully restored metastatic capacity in in vivo models. Co‐expression of CTH and HIF1α proteins was also observed in human CCOC samples. Importantly, targeting CTH in CCOC significantly reduced its metastatic potential in in vivo models and enhanced sensitivity to chemotherapy. These findings underscore that CTH is both a defining feature of CCOC and a promising therapeutic target, not only for CCOC patients but also for those with other CTH‐expressing cancers. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Year:

2025

Supplementary Table 1. Logistic regression analysis of factors associated with accepting risk-reducing surgery (RRS) for ovarian cancer when lifetime risk is less than 4% compared to greater or equal to 4%, using complete case analysis

Year:

2025

Tumor protein p53 mutated/abnormal (p53abn) endometrial carcinomas account for over 50% of deaths but comprise only 15% of all endometrial carcinomas. Most patients show limited response to standard‐of‐care chemotherapy with or without radiotherapy, and only a minority of cases are amenable to targeted therapies like poly‐ADP ribose polymerase (PARP) inhibitors and HER2‐directed therapies. Recent immunotherapy clinical trials have demonstrated remarkable efficacy, not only in mismatch repair deficient (MMRd) tumors but also in a subset of mismatch repair‐proficient (MMRp) tumors. However, the immune microenvironment and its relationship to other therapeutic targets in MMRp endometrial carcinoma remains poorly understood. Here, we characterize the immune microenvironment of p53abn endometrial carcinoma, the most clinically aggressive subtype of MMRp endometrial carcinoma, and correlate antitumor immune signatures with other targetable alterations. We accrued 256 treatment‐naïve p53abn endometrial carcinomas and systemically profiled T‐cell, B‐cell, myeloid, and tumor‐cell populations with multiplex immunofluorescence to assess the tissue localization and functional status of immune cells. Shallow whole‐genome sequencing was performed on a subset of 126 cases. Patterns of immune infiltration were compared to survival outcomes and mutational signatures. Mixture modeling divided p53abn endometrial carcinoma into tumor‐infiltrating lymphocyte (TIL)‐rich and TIL‐poor subsets. Over 50% of tumors were TIL‐rich. TIL‐rich cases overexpressed targetable immune evasion molecules and were associated with longer overall and disease‐specific survival in multivariate analysis. This effect was particularly pronounced in advanced stage disease and in patients who did not receive adjuvant chemotherapy. TIL did not associate with homologous recombination deficient mutational signatures or HER2 amplification. Our findings demonstrate a biological rationale for immunotherapy in a substantial subset of patients with p53abn endometrial cancer and may help inform combination therapies with immune checkpoint inhibition, PARP inhibitors, and anti‐HER2 agents. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Year:

2025

With evidence that salpingectomy is effective in preventing high-grade serous carcinoma, it is time to consider offering this procedure to people at higher-than-average lifetime risk for ovarian cancer, despite not having a pathogenic genetic variant that increases the risk for ovarian cancer. This targeted approach has potential to be effective at reducing ovarian cancer incidence, and unlike opportunistic salpingectomy, it is focused on people with an increased lifetime risk of ovarian cancer. However, the acceptability of this approach within the population of potential patients remains unknown. We conducted an online survey of adults in British Columbia, Canada, who were defined as “at risk” for ovarian cancer (i.e., people born with ovaries). Participants completed a questionnaire on demographics, ovarian cancer risk and protective factors, concerns about risk-reducing salpingectomy (RSS), and the risk they considered high enough to warrant RRS. We included 211 participants. Among these participants, 42% ( n = 88) indicated that they would consider RRS at any lifetime risk or any risk above the population average. Another 20 participants chose risks between 1.5% and 4% for a cumulative 51% of the sample choosing risks below thresholds for oophorectomy. In contrast, 6% ( n = 12) indicated that they would not consider the procedure at any risk level. None of the factors collected were associated with the likelihood that a person would find RRS acceptable. Overall, our participants showed broad interest in RRS as an ovarian cancer prevention strategy. These results suggest that there would likely be uptake if RRS was offered. Significance: This study found that many participants were willing to consider RRS to prevent ovarian cancer. Further research on RRS should be undertaken to understand how this can be best used for ovarian cancer prevention.

Year:

2025

Supplementary Table 1. Logistic regression analysis of factors associated with accepting risk-reducing surgery (RRS) for ovarian cancer when lifetime risk is less than 4% compared to greater or equal to 4%, using complete case analysis

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (86)

Jessica N. McAlpine

Chew Wei Chair Gynecologic Oncology, Division Head

The University of British Columbia

CANADA
View details

Charlie Gourley

University of Edinburgh

UNITED KINGDOM
View details

Sue K. Park

Professor

Seoul National University College of Medicine

SOUTH KOREA
View details

Elizabeth Christie

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Timothy Budden

Lecturer

University of Liverpool

UNITED KINGDOM
View details

Beth Karlan

Vice Chair

University of California, Los Angeles

UNITED STATES
View details

William Foulkes

Full Professor

McGill University

CANADA
View details

Anna Jakubowska

Head

Pomeranian Medical University

POLAND
View details

Lynne Wilkens

Professor

University of Hawaii at Manoa

UNITED STATES
View details

Ritin Sharma

Staff Scientist

Translational Genomics Research Institute

UNITED STATES
View details

Anthony Swerdlow

Professor of Epidemiology

Institute of Cancer Research Sutton

UNITED KINGDOM
View details

Walter H Gotlieb

McGill University

CANADA
View details

Matthew Wakefield

University of Melbourne

AUSTRALIA
View details

Martin Widschwendter

Professor; Director

University of Innsbruck

AUSTRIA
View details

Martin Köbel

Associate Professor

University of Calgary

CANADA
View details

Estrid V. Hoegdall

University of Copenhagen

DENMARK
View details

Minh Tung Phung

Assistant Professor

University of Wisconsin-Madison

UNITED STATES
View details

Huihui Fan

Assistant Professor

The University of Texas Health Science Center at Houston John P and Katherine G McGovern Medical School

UNITED STATES
View details

Paul Timpson

Co-Director ACRF (INCITe) Centre

Garvan Institute of Medical Research

AUSTRALIA
View details

James D Brenton

University of Cambridge

UNITED KINGDOM
View details

Jae-Weon Kim

Professor

Seoul National University Hospital

SOUTH KOREA
View details

Alexander Bishop

Professor

University of Texas Health Science Center at San Antonio

UNITED STATES
View details

Cezary Cybulski

Pomeranian Medical University

POLAND
View details

Lyndal Anderson

University of Western Sydney

AUSTRALIA
View details

Claus Høgdall

Professor in Clinical Gynecologic Oncology

University of Copenhagen

DENMARK
View details

Gregg Morin

Associate Professor

The University of British Columbia

CANADA
View details

Morag Park

McGill University

CANADA
View details

Hui Shen

Van Andel Institute

UNITED STATES
View details

Anthony Gill

University of Sydney

AUSTRALIA
View details

Linda Cook

Professor

University of Colorado Cancer Center

UNITED STATES
View details

Paul James

Head of Adult Genetics

The Royal Melbourne Hospital Royal Park Campus

AUSTRALIA
View details

Parham Minoo

Associate Clinical Professor of Pathology

University of Calgary

CANADA
View details

Angela Brooks-Wilson

Simon Fraser University

CANADA
View details

Bernard E. Weissman

University of North Carolina at Chapel Hill School of Medicine

UNITED STATES
View details

Tomasz Kluz

Professor

Rzeszów University

POLAND
View details

Joellen Schilkdraut

Professor

Emory University

UNITED STATES
View details

Michael Anglesio

Associate Professor

The University of British Columbia

CANADA
View details

Ramona Erber

W2-Professorin, Oberärztin

University of Regensburg

GERMANY
View details

Nicholas Hawkins

Emeritus Professor

UNSW Sydney

AUSTRALIA
View details

Usha Menon

Professor of Gynaecological Oncology

University College London

UNITED KINGDOM
View details

yvette drew

Associate Professor

The University of British Columbia

CANADA
View details

Lynda Bennett

Assistant Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Sandra Orsulic

Professor

University of California, Los Angeles

UNITED STATES
View details

Cheng-Han Lee

Associate Professor

University of Alberta

CANADA
View details

Ian Campbell

Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Stacey J. Winham

Mayo Clinic College of Medicine and Science

UNITED STATES
View details

Kathleen Cho

University of Michigan

UNITED STATES
View details

Rafael Meza

Distinguished Scientist

University of Michigan

UNITED STATES
View details

Elise Graulich

University of Geneva

SWITZERLAND
View details

Jae-Hoon Kim

Yonsei University College of Medicine

SOUTH KOREA
View details

Anna H. Wu

Professor

University of Southern California

UNITED STATES
View details

Marcin Kortylewski

Professor

Beckman Research Institute, City of Hope

UNITED STATES
View details

Gillian Hanley

Associate Professory

The University of British Columbia

CANADA
View details

C Blake Gilks

-

CANADA
View details

Peter Fasching

-

GERMANY
View details

Francesmary Modugno

University of Pittsburgh

UNITED STATES
View details

Brooke E. Howitt

Stanford University School of Medicine

UNITED STATES
View details

Alexander Hein

-

GERMANY
View details

Kylie-Ann Mallitt

Senior Lecturer in Biostatistics

University of Sydney

AUSTRALIA
View details

Dale Garsed

University of Melbourne

AUSTRALIA
View details

Philip Crowe

Professor Surgery

University of New South Wales

AUSTRALIA
View details

Renée Fortner

Head of Division

Deutsches Krebsforschungszentrum

GERMANY
View details

K Sundfeldt

Professor/Consultant

University of Gothenburg, Sahlgrenska Academy

SWEDEN
View details

Tomasz Huzarski

Pomeranian Medical University

POLAND
View details

Byoung-Gie Kim

Sungkyunkwan University School of Medicine

SOUTH KOREA
View details

Dane Cheasley

Senior Research Fellow

University in Western Australia

AUSTRALIA
View details

Gregg Nelson

Gynecologic Oncologist

University of Calgary

CANADA
View details

Sidong Huang

McGill University

CANADA
View details

Jennifer Anne Doherty

Professor

University of Utah

UNITED STATES
View details

Jessica Lang

Assistant Professor

University of Wisconsin-Madison

UNITED STATES
View details

Tully Underhill

Professor

The University of British Columbia

CANADA
View details

Paul Pharoah

Professor of Cancer Epidemiology

Cedars-Sinai Medical Center

UNITED STATES
View details

Brenda Y Hernandez

University of Hawaii

UNITED STATES
View details

Michael Edwin Jones

Senior Staff Scientist

Institute of Cancer Research

UNITED KINGDOM
View details

Kylie L Gorringe

Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Jan Lubiński

Head of Dept

Pomeranian Medical University

POLAND
View details

Mona El-Bahrawy

Imperial College London

UNITED KINGDOM
View details

Yemin Wang

Assistant Professor

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Aleksandra Gentry-Maharaj

University College London

UNITED KINGDOM
View details

Janusz Menkiszak

Head of the University Clinic

Pomeranian Medical University

POLAND
View details

Fuchsia Howard

Associate Professor

The University of British Columbia

CANADA
View details

Clare Scott

Walter and Eliza Hall Institute of Medical Research

AUSTRALIA
View details

Susan Ramus

Professor of Molecular Oncology

University of New South Wales

AUSTRALIA
View details

Paul Cohen

University of Western Australia

AUSTRALIA
View details

Aline Talhouk

Assistant Professor

The University of British Columbia

CANADA
View details

David Lawson Morris

Professor of Surgery

University of New South Wales

AUSTRALIA
View details